Summary Plasma concentrations, after administration of varying doses of nicotinamide, were measured in CBA male mice using a newly-developed high performance liquid chromatography assay. In all dose groups, peak levels were observed within the first 15 min after an i.p. administration of 0.1, 0.2, 0.3 or 0.5 mg g' of nicotinamide. There was a clear dose-dependent increase in plasma concentration with increasing dose, with almost a five-fold lower concentration (1.0 vs 4.9 1mol ml-') achieved with a dose of 0.1 mg g' compared with 0.5 mg g ', respectively. The half-life of nicotinamide increased from 1.4 h to 2.2 h over the dose range (P<0.01). Comparisons with previous pharmacokinetic data in humans show that clinically-relevant oral doses of 6 and 9 g in humans give plasma levels slightly higher than those achieved at 1 h with doses of 0.1 to 0.2mgg ' in mice.
Although hypoxia can be a limiting factor in radiotherapy, many of the clinical trials with oxygen and oxygen-mimetic compounds have shown little or no effect (Dische, 1983) . Cumulative toxicity of chemical radiosensitisers, tumour heterogeneity and the small number of patients entered into many of the trials can explain in part the failure of most of these to show a benefit. However, the Dahanca studies show that if an appropriate number of well stratified patients are included in a trial, a significant gain can be obtained with radiosensitisers (Overgaard et al., 1991) . Moreover, a metaanalysis of all the data from randomised trials shows a significant advantage in patients where some form of hypoxic manipulation was done, especially for head and neck tumours (Overgaard, 1992) . Clinical expectations with chemical radiosensitisers were based on animal studies with large single doses of the drug (mainly misonidazole) and radiation, and these overestimated the gain that could be achieved clinically. Most of the fractionated X-ray rodent tumour data, however, indicated a decrease in radiosensitisation as the dose per fraction was decreased (Fowler & Denekamp, 1979; Hill, 1986) , and are therefore consistent with the much reduced benefit seen in patients.
By contrast with oxygen-mimetic radiosensitisers, the combination of carbogen (95%02 + 5% C02) with nicotinamide, the amide form of vitamin B3, has been shown to be a potent, non-toxic and preferential tumour radiosensitiser both in single dose and fractionated X-ray regimes in mice (Chaplin et al., 1991; Kjellen et al., 1991) . It has also been shown that the sensitising efficacy of the combination tends to increase with fractionation and enhancement ratios of over 2 have been seen at small clinically-relevant radiation doses per fraction (Rojas, 1992) . Furthermore, a large therapeutic gain (relative to mouse kidney, lung, gut, spinal cord and, to a lesser degree, skin) is obtained with carbogen combined with nicotinamide (Haustermans et al., 1992; Kjellen, et al., 1991; Rojas, et al., unpublished) . In mice, skin is under uniform moderate hypoxia and is very responsive to vasoactive stimuli, and therefore overestimates the degree of radiosensitisation likely to be seen in other normal tissues Correspondence: A. Rojas, CRC Gray Laboratory, PO Box 100, Mount Vernon Hospital, Northwood, Middlesex HA6 2JR, UK.
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Pharmacokinetic studies in human volunteers show that plasma levels of 0.7-1.6 tmolml1' can be obtained after a single oral dose of 6g of nicotinamide (Horsman, 1992; Horsman et al., 1993) . Previous animal studies with carbogen plus nicotinamide (CON) using fractionated X-ray schedules have been performed with a nicotinamide dose per fraction of 0.5 mg g-', which is about 3 to 5 times higher than could safely be used in man (Green, 1970; Hawkins, 1968; Hoffer, 1971; Zackheim, 1981) . There is now an interest in using carbogen with nicotinamide in radiotherapy (Bernier & Bartelink, 1992, pers. comm; Laddaga, 1992, pers. comm; Littbrand, 1992, pers. comm; Saunders & Dische, 1991, pers. comm) . To predict the possible clinical gain with this approach, we determined tumour radiosensitisation with carbogen combined with varying doses of nicotinamide in fractionated X-ray schedules, using both a local tumour control and an excision assay. We also investigated plasma pharmacokinetics in mice with similar sized doses of nicotinamide, which could then be compared with the human pharmacokinetic studies (Horsmann et al., 1993; Stratford et al., unpublished) .
Materials and methods
Adult CBA/GyfBSVS male mice were used in all these experiments, which were conducted under the regulations stipulated by the UK Animals (Scientific Procedures) Act, 1986.
Pharmacokinetic studies Non-tumour bearing mice, 10 to 15 weeks old, were allocated randomly to treatment groups of two animals and fed and watered ad lib throughout the procedure. Nicotinamide (Sigma) doses of 0.1, 0.2, 0.3 and 0.5 mg g' were used and dissolved in saline at concentrations of 10 to 50 mg ml-'. At various times after 0.01 ml g' i.p. injection, 0.5 ml blood samples were obtained in heparinised tubes from the mice after decapitation and plasma was separated by centrifugation within 15 min of sampling. Plasma aliquots of 100 tl1
were stored at -20°C prior to analysis by HPLC (high performance liquid chromatography) using the technique of . Briefly, to 100 ,l of plasma was added 20 nmol of 6-methylnicotinamide (as an internal standard) followed by 1 ml methanol. There was no consistent difference in cell yield nor in tumour weight in the different treatment groups. All dishes were incubated (under an atmosphere of 5% 02, 5% C02, balance nitrogen) at 37°C for 10 days, after which the medium was removed and the colonies were then fixed and stained with 0.2% crystal violet in 70% ethanol.
Enhancement ratios Iso-effective doses (± 95% CL), obtained from the logit fits to the local control probability data, were used to calculate enhancement ratios (ERs) as the ratio of the X-ray dose in air to the dose with the sensitiser combination at the same level of damage. Dose response curves drawn through the survival data ( Figure 3) were obtained by fitting a third-order polynomial equation to the logarithmically transformed surviving fraction (SF)$ of each individual tumour against dose, using non-linear least-squares regression. The parameters obtained from the fits to each survival dose-response curve were then used to calculate iso-effective doses (± 95% CL), and from these, enhancement ratios at three different levels of survival were obtained in the manner described above. The significance of differences in the dose-modifying factors between dose-response curves, for the different treatment groups, was estimated by carrying out a t-test on pairs of enhancement ratios and their respective errors.
Results
Plasma clearance after a single i.p. injection of 0.1-0.5mgg-' of nicotinamide in CBA mice is shown in Figure 1 . There was rapid absorption of the compound and peak plasma levels occurred for all dose groups within the first 10-15 min. The levels achieved were dose dependent, with a nearly five-fold lower peak concentration for 0.1 mg g-compared with 0.5 mg g-l. For all dose levels the clearance was linear in the first 3-6 h. The fits to the data were calculated, over the time intervals indicated in Figure 1 , using non-linear least squares regression; the apparent halflives are shown in Table I MeaPlating efficiency of treated tumours Mean plating efficiency of control tumours Radiosensitisation with carbogen alone was significantly lower in the excision assay than in the local control assay. Our earlier experience with normobaric oxygen and carbogen has been that larger ERs are generally seen with local tumour control than with other assays in which less cell kill is induced (Rojas et al., 1990a) . With CON, radiosensitisation was non-significantly less with the excision assay than that observed with local control probability (Table II cf Table  III) . With the former assay, ERs increased with increasing level of cell kill for all 6 different sensitiser combinations. Above 5 x 101 surviving fraction no sensitising effect was observed. At the lower levels of cell survival radiosensitisation with this assay was similar to that seen with local tumour control. With this assay, ERs at the TCD50 level (dose required to control 50% of tumours) were similar to those calculated at other levels of effect (data not shown).
Time after injection (h) dose of nicotinamide was increased but the difference was significant only when comparing 0.1 mg g-' with the other doses (P<0.01). Figure 2 shows dose-response curves from two separate local tumour control experiments, in mice breathing air alone, carbogen alone, or carbogen with 0.1-0.5 mg g' nicotinamide injected 1 h before each fraction. The responses in all repeat schedules were remarkably similar, and there was no significant difference in the isoeffective doses obtained when the fits were done separately for each experiment (data not shown). Therefore, the fits shown in Figure 2 Figure 3 . Relative to air, radiosensitisation was seen with all CON treatments but the magnitude of the effect was radiation dose dependent; below 0.5 Gy per fraction sensitisation was not observed. Nicotinamide doses of 0.05 to 0.3 mg g' all gave similar enhancements of tumour damage and these were significantly lower than those observed with the two highest doses tested. Carbogen alone gave a small but significant increase in radiosensitisation.
Tables II and III summarise the enhancement ratios for the different combinations investigated with both assays compared with treatments under air-breathing conditions. Relative to air, all ERs were significantly different (Tables IV  and V) . There was a trend towards a progressive increase in radiosensitisation as the dose of nictotinamide was increased.
Discussion
In experimental radiotherapy, tumour radiosensitisation with carbogen combined with nicotinamide differs from that seen with other oxygen-mimetic radiosensitisers in that the benefit does not decrease with fractionation. At a clinically relevant radiation dose per fraction of 2 Gy, enhancement ratios of 1.9 and 2.1 have been observed with carbogen plus 0.5 mg g-' of nicotinamide (Rojas, 1992) . Since a large and significant therapeutic gain has been seen in mice (Haustermans, 1992; Kjellen et al., 1991; Rojas et al., unpublished) , CON could be a very effective and non-toxic sensitiser for use in humans. In clinical radiotherapy however, the effectiveness of the carbogen-nicotinamide combination will be limited by the dose of nicotinamide that can be administered to patients, by the ability of carbogen to increase tumour PO2, and by the extent of normal tissue sensitisation.
Until now, all the fractionated radiation studies with CON in rodents have been carried out with nicotinamide doses of 0.5 mg g 1, which are above those that can be realistically achieved in man. The vitamin has been used extensively in human dermatological and psychiatric disorders, and more recently, in the prevention and treatment of diabetes type I (Green, 1970; Hawkins, 1968; Hoffer, 1971; Vague et al., 1989) . Doses of up to 12g per day (-0.17mgg' for a 70 kg man) have been administered over many months. Few side-effects, all of which are reversible, have been reported in the literature (Hoffer, 1971; Winter & Boyer, 1973; Zackheim et al., 1981) . Two surveys conducted in the USA reported that the major limiting toxicity with the vitamin was liver failure, with an incidence of one in 2000-3000 patients (Zackheim et al., 1981) . Therefore, from a drug toxicity point of view, 6-9g (-0.09-0.13mgg-1 for a 70kg man) per day for the duration of an accelerated or a conventional radiotherapy regime should be feasible.
Our studies show that nicotinamide doses of 0.05 to 0.5 mg g', when combined with carbogen, significantly increase the radiosensitivity of rodent CaNT tumours compared with fractionated X-ray treatments under air-breathing conditions (Figures 2 and 3) . Enhancement ratios obtained with CON (0.05-0.5 mg g-1) were significantly larger than those seen with carbogen alone (Tables IV and V ). In the local control assay, although the ER for CON (0.1 mg g-') was greater than that for carbogen alone, it failed to reach significance. Carbogen alone is an effective radiosensitiser but its efficacy varies from one experiment to another; an ER as low as 1.2 was seen in CaNT tumours using the same fractionated regime (Kjellen et al., 1991; Rojas, 1992 ). By contrast, the combination of carbogen with nicotinamide gives large and reproducible enhancements of tumour damage (Rojas, 1992 ; these data). In mice, there is no evidence of treatment associated toxicity with CON either in conventional schedules with 30 fractions in 6 weeks or in accelerated regimes with 20-40 fractions in 3-4 weeks (Rojas et al., unpublished) . In the present study nicotinamide plasma concentration in CBA mice was linearly related to administered dose on a mg g' basis; a similar linear relationship has also been observed in CDF1 mice and humans (Horsman, 1992; Horsman et al., 1993; . Figure 4 shows peak plasma levels in man compared with peak levels and levels at 1 h in rodents. A single oral dose of either 6 or 9 g of nicotinamide in man achieved a peak concentration comparable with peak levels obtained in mice after an i.p. administration of 0.1 or 0.2 mg g-', respectively (Horsman et al., 1993; Stratford et al., unpublished) . With the local control assay, a decrease of about 5% in the efficacy of CON was seen when the dose of nicotinamide was reduced from 0.5 to 0.3 and 0.2mg g', and a further 10% reduction when reduced to 0.1 mg g '. Although there was almost a three-fold difference in plasma concentration between 0.5 mg g-' and 0.2 mg g-' (Figure 4, top) , only a small further gain in local control is achieved with CON by increasing the dose of nicotinamide above 0.2 mg g'. As shown in Figure 4 (bottom), the change in radiosensitisation in vivo over a range of nicotinamide plasma levels is best fitted by an exponential rather than by a linear relationship (the exponential fit gives a lower residual sum of errors). Others have previously reported a similar finding for nicotinamide alone but at a higher drug-dose level (Horsman et al., 1989) . Relative to air breathing mice, significant sensitisation is seen with CON at nicotinamide plasma concentrations of 0.7-1.6 iimol ml-' that are achieved in humans (Table I cf. Figure 4) . Peak plasma levels seen in man indicate that 6 and 9 g doses, if combined with carbogen, could achieve ERs higher than those observed in mice with 0.1-0.2 mg g' of nicotinamide (Table I; stration and irradiation, which is about 30 min after peak concentrations are observed in CaNT tumours (Stratford & Dennis, in preparation) . Previously, Horsman et al. (1989) showed tumour sensitisation decreased with decreasing dose of nicotinamide, and only a 10% increase in radiosensitivity could be obtained with 0.1-0.2 mg g-'. However, by reducing the interval between injection and irradiation to 20 min, (i.e. the time at which peak tumour levels were seen for all dose levels), they showed that ERs with 0.1-0.2 mg g-' were comparable to those obtained with 0.4-1.0 mg g '. This suggests that concentration at the time of irradiation is the factor that mainly determines the degree of tumour radiosensitisation (Horsman et al., 1993) . However, if length of exposure to nicotinamide plays any role in tumour radiosensitisation, a dose of 6 g in man could be more effective than 0.1 mg g-' in the mouse, since the half-life of the vitamin in man is 3-8 times longer than that in rodents (Table I) . Enhancement ratios in vivo with CON reported here and at lower doses per fraction (Rojas, 1992) (Horsman et al., 1987; Rojas et al., 1990b; Joiner et al., unpublished) , nicotinamide can change the slopes of tumour cell survival curves, suggesting that the radiosensitisation observed was not only due to a reduction in the fraction of hypoxic cells (Horsman et al., 1987) . Microelectrode measurements show that carbogen is very effective at increasing PO2 in human tumours within 2-O min of breathing the gas (Falk et al., 1992; Martin et al., 1993) , and no toxic side-effects are seen in patients even when administered for periods of up to 2 h each day Rubin et al., 1979) . Although in a large series of patients treated with carbogen and radiotherapy there was no evidence of increased early or late morbidity (Rubin et al., 1979) , in a small, more recent, series of patients one case of radiation myelitis and one of skin necrosis did occur ; and with hyperbaric oxygen increased morbidity was observed in cartilage, bowel and spinal cord (Dische, 1983) . A palliative, pilot study of 6 fractions in 21 days in Ca breast has shown no evidence of increased acute normal tissue reactions in patients treated with a 6 g dose of nicotinamide given 1.5 h before each fraction plus carbogen given 4-O min before and during treatment (Saunders & Dische, 1991, pers. comm) . However, some degree of normal tissue sensitisation should be anticipated with CON in clinical radiotherapy, and spinal cord and cartilage are of particular concern.
There is considerable interest in the clinical application of carbogen and nicotinamide in both palliative and curative radiotherapy. Animal data now show that very effective radiosensitisation in clinically-relevant experimental regimes can be obtained by combining these methods of attacking tumour hypoxia, and mouse-man comparisons suggest that CON could be a most effective and non-toxic radiosensitiser for use in clinical radiotherapy. However, more laboratory work must be done to assess further its therapeutic potential, to identify tumour parameters that can be used as prognostic indicators and to identify the intrinsic mechanism(s) of action of nicotinamide.
